학술논문
KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755